PMID- 16567077
OWN - NLM
STAT- MEDLINE
DCOM- 20060811
LR  - 20081121
IS  - 0748-7983 (Print)
IS  - 0748-7983 (Linking)
VI  - 32
IP  - 5
DP  - 2006 Jun
TI  - The role of salvage surgery for recurrence of esophageal squamous cell cancer.
PG  - 544-7
AB  - AIM: A consensus treatment strategy for recurrent esophageal squamous cell cancer 
      (ESCC) has not been established. The purpose of the present study was to analyse 
      the mode of recurrence, and evaluate the role of surgical salvage treatment in 
      recurrence of ESCC. METHODS: Recurrence was detected in 131 of 367 consecutive 
      patients with ESCC. We retrospectively analysed the mode of recurrence and 
      treatment for recurrence. Recurrence was divided into four types; lymph node, 
      hematogeneous, mixed and local. Treatments were classified into four groups; 
      chemotherapy alone (C group), radiation therapy +/- chemotherapy (R group), 
      surgery +/- other therapy (S group), and no therapy (N group). RESULTS: Of the 
      131 recurrences, the number of patients with lymph node, hematogeneous, mixed and 
      local recurrence was 43, 44, 40 and 4, respectively. The number of patients in 
      the C, R, S, N groups was 35, 35, 24 and 37, respectively. Of the 24 patients who 
      received surgical treatment for recurrence, the number of patients with lymph 
      node, hematogeneous, mixed and local recurrence was 11, 6, 6 and 1, respectively. 
      The number of lesions in hematogeneous recurrence was 2 or less. The survival 
      rate from recurrence to death in the C, R, S and N groups was 0, 3.9, 6.7 and 0%, 
      respectively. A statistically significant difference was found in these groups (p 
      < 0.0001). CONCLUSIONS: Salvage surgery is one of the useful treatment tools for 
      resectable metastatic lesions. In such cases, the number of lesions, recurrent 
      sites and effectiveness of chemotherapy and/or radiotherapy should be carefully 
      evaluated.
FAU - Natsugoe, S
AU  - Natsugoe S
AD  - Department of Surgical Oncology and Digestive Surgery, Kagoshima University 
      School of Medicine, Japan. natsugoe@m2.kufm.kagoshima-u.ac.jp
FAU - Okumura, H
AU  - Okumura H
FAU - Matsumoto, M
AU  - Matsumoto M
FAU - Uchikado, Y
AU  - Uchikado Y
FAU - Setoyama, T
AU  - Setoyama T
FAU - Uenosono, Y
AU  - Uenosono Y
FAU - Ishigami, S
AU  - Ishigami S
FAU - Owaki, T
AU  - Owaki T
FAU - Aikou, T
AU  - Aikou T
LA  - eng
PT  - Journal Article
DEP - 20060329
PL  - England
TA  - Eur J Surg Oncol
JT  - European journal of surgical oncology : the journal of the European Society of 
      Surgical Oncology and the British Association of Surgical Oncology
JID - 8504356
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/therapeutic use
MH  - Carcinoma, Squamous Cell/secondary/*surgery
MH  - Chemotherapy, Adjuvant
MH  - Esophageal Neoplasms/*surgery
MH  - Esophagectomy
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Lymph Node Excision
MH  - Lymphatic Metastasis/pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/*surgery
MH  - Neoplastic Cells, Circulating/pathology
MH  - Radiotherapy, Adjuvant
MH  - Retrospective Studies
MH  - *Salvage Therapy
MH  - Survival Rate
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2006/03/29 09:00
MHDA- 2006/08/12 09:00
CRDT- 2006/03/29 09:00
PHST- 2005/09/13 00:00 [received]
PHST- 2006/02/17 00:00 [accepted]
PHST- 2006/03/29 09:00 [pubmed]
PHST- 2006/08/12 09:00 [medline]
PHST- 2006/03/29 09:00 [entrez]
AID - S0748-7983(06)00069-2 [pii]
AID - 10.1016/j.ejso.2006.02.014 [doi]
PST - ppublish
SO  - Eur J Surg Oncol. 2006 Jun;32(5):544-7. doi: 10.1016/j.ejso.2006.02.014. Epub 
      2006 Mar 29.